In our first 2 episodes, we brought you multi-stakeholder discussions of biosimilar interchangeability and nonmedical switching.

Today, we’re changing gears and bringing you a perspective from the business side of biosimilars. Our guest on this episode of "Not So Different" is Jim Van Lieshout, MBA.

Van Lieshout is a consultant with 37 years of experience in developing market access strategies for pharmaceutical companies. Most recently, Van Lieshout worked in the Apotex family of companies, as vice president of trade and industry relations for Apobiologix. He joined us by phone from Colorado to discuss the many considerations that biosimilar developers must take into account when they determine how to price their products to compete in the marketplace.

Podcasts

Our guest on this episode of "Not So Different" is Jim Van Lieshout, MBA, who joined us by phone from Colorado to discuss the many considerations that biosimilar developers must take into account when they determine how to price their products to compete in the marketplace.
 

"Not So Different" Episode 3: Pricing

In our first episode, we brought you a discussion of biosimilar interchangeability from experts across the biosimilars landscape. Interchangeable biosimilars haven’t yet become a reality in the US marketplace, and, as of yet, there is no pharmacy-level substitution of interchangeable biosimilars for brand-name products.

However, patients and their providers may still face a change of biologic therapies when payers institute a nonmedical switch.

In today’s episode of Not So Different, you’ll hear providers and patient advocates on the issue of nonmedical switching among brand-name biologics and biosimilars in rheumatology and oncology indications.

In this episode of Not So Different, you’ll hear providers and patient advocates on the issue of nonmedical switching among brand-name biologics and biosimilars in rheumatology and oncology indications.

Episode 2 of "Not So Different: a Podcast From the Center for Biosimilars"  

The introduction of biosimilars into the US marketplace has been cause for both excitement and concern, as these products hold the potential to drive down costs and increase patient access, but face significant challenges to uptake. One of those challenges is interchangeability.

Federal law provides for interchangeable biosimilars, but the FDA has not yet granted that status to any biosimilar product, and hasn’t finalized its guidance on demonstrating interchangeability with a reference product. In this episode of "Not So Different," you’ll hear expert viewpoints on the issue of interchangeability from stakeholders across the biosimilars landscape.

In this innaugural episode of "Not So Different," you’ll hear expert viewpoints on the issue of interchangeability from stakeholders across the biosimilars landscape.

 

Podcasts

"Not So Different" Episode 3: Pricing

Episode 2 of "Not So Different: a Podcast From the Center for Biosimilars"

Introducing "Not So Different: a Podcast From The Center for Biosimilars"